From 2 KEY POINTS
INTRODUCTION
While the success of TKIs as first line therapy for CML in chronic phase (CML-CP) is fully justified by the BCR-ABL1 kinase-dependence of leukemic progenitors, the etiopathogenesis of Ph + acute leukemias is still unclear 1-3 . In fact, the presence of BCR-ABL1 mutations and nonrandom secondary genetic abnormalities can only partially explain the lack of long-term response and/or development of resistance to TKIs (including ponatinib) and other therapeutic options 1,4-8 . Thus, the biological processes underlying emergence and maintenance of CML-BC and Ph + B-cell ALL likely involve different combinations of BCR-ABL1-independent genetic or epigenetic (cell-autonomous and microenvironment-induced) molecular events in addition to BCR-ABL1 oncogene-driven mechanisms occurring in a kinase-dependent and -independent manner 1, 9, 10 . Post-transcriptional control of gene expression (mRNA processing, stability, export and translation) plays an essential role in the emergence, maintenance and/or progression of different types of cancer including Ph + acute leukemias 1, [11] [12] [13] [14] [15] . In these hematologic malignancies, altered expression and activity of the nucleocytoplasmic shuttling heterogeneous ribonuclear proteins (hnRNPs) results in aberrant metabolism of their mRNA cargo that in most cases encompasses oncogenes, tumor suppressor proteins (TSPs) and growth/survival-or differentiation-regulating factors 11, 15 . Karyopherins also function to mediate the nucleocytoplasmic exchange of proteins and RNA through nuclear pore complexes 14, [16] [17] [18] .
Specifically, the karyopherin β family member XPO1 (exportin-1, also called CRM1) is a critical regulator of cell proliferation and survival [19] [20] [21] [22] that is overexpressed in several hematologic and non-hematologic malignancies in some of which it was described as a poor prognostic factor [22] [23] [24] [25] [26] [27] [28] [29] [30] . Different inhibitors of XPO1-mediated export through the nuclear pore complex have been developed 31 ; among these, the selective inhibitors of nuclear export (SINE, Karyopharm Therapeutics Inc.) are small molecules based on leptomycin B (LMB) that irreversibly bind to Cys528 in the cargo-binding groove of XPO1 to prevent XPO1-cargo interaction 22, [24] [25] [26] 32 .
Preclinical in vitro and/or in vivo studies have shown that the closely-related SINE compounds have strong anti-leukemic activity in AML, T-cell ALL, mantle-For personal use only. on October 24, 2017. by guest www.bloodjournal.org From cell lymphoma and CLL, likely through signals mediated by altered subcellular localization of p53, IκBα and/or FoxO3a 22, [24] [25] [26] 32 . Notably, the SINE KPT-330 is currently in clinical trials for advanced hematologic malignancies and solid tumors (NCT01607892 and NCT01607905).
Here we report that XPO1 is also overexpressed in Ph + acute leukemias, and that SINEmediated XPO1 inhibition decreases survival of leukemic but not normal CD34 + progenitors, thereby impairing leukemogenesis both in vitro and in an animal model of Ph + acute leukemia.
Mechanistically, KPT-330-induced inhibition of XPO1-mediated nuclear export not only altered subcellular localization of p53, IκBα and FoxO3a but, importantly, it directly subverted the BCR-ABL1-hnRNP A1-SET network 33 thereby restoring the activity of the protein phosphatase 2A (PP2A) tumor suppressor, an event sufficient to selectively kill CML-BC and Ph + ALL blasts 34 .
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From 1 0 ABL1-dependent and -independent leukemogenic signals. This is also supported by the evidence that KPT-330 specifically binds only XPO1, and interacts but not inhibits Aurora A and p70S6 kinases at 10 μM concentration in functional LANCE ® TR-FRET assays (data not shown).
Molecular mechanisms of KPT-330 anti-leukemic activity in BCR-ABL1 + cells.
Because XPO1 is predicted to target hnRNP A1 38 , and has been shown to directly interact with both BCR-ABL1 39 and the PP2A inhibitors SET 40 and CIP2A 41 , we sought to investigate whether KPT-330-induced apoptosis of Ph + leukemic blasts depends, at least in part, on interference with the BCR-ABL1/Jak2-induced hnRNP A1/SET pathway responsible for inhibition of PP2A tumor suppressor activity in Ph + acute leukemias 15, 33, 34 (Figure 3 ). Confocal microscopy and Western blot of subcellular fractionated lysates revealed that treatment of 32D-BCR/ABL cells with 12h) sequestered the SET and CIP2A proteins in the nucleus, without altering the subcellular localization of PP2Ac ( Figure 3A-B) . Similarly, KPT-330 treatment also resulted in altered subcellular localization of hnRNP A1 that, surprisingly, accumulated in the cytoplasm rather than in the nucleus of 32D-BCR/ABL cells ( Figure 3A-B ). Interestingly, localization of HA-tagged shuttling-deficient hnRNP A1 mutants 35 carrying either the G274A mutation in the nuclear import/export M9 domain (hnRNP A1-G274A-HA), which makes hnRNP A1 protein cytoplasmic, or a bipartite-basic-type nuclear localization signal (NLS) together with the G274A mutation, which has a defined nuclear localization, was not altered upon inhibition of XPO1 activity by treatment with KPT-330 (Supplemental Figure 2 ), suggesting that the integrity of the M9 domain is important for the effect of XPO1 on both hnRNP A1 localization and nuclear export of hnRNP A1 mRNA cargo. Moreover, consistent with the effect of KPT-SINE compounds in other hematologic malignancies 22, [24] [25] [26] [27] [28] [29] [30] 32 , confocal microscopy ( Figure 3A ) and subcellular fractionation ( Figure 3C ) analyses revealed that KPT-330-treatment (1 µM, 72 hours) induced a nuclear accumulation of IkBα, FoxO3a and p53, and enhanced levels of the p53target p21. Conversely, we did not observe a nuclear accumulation of either p210 or p190 BCR-1 1 ABL1 (not shown); however, both p190 and p210 BCR-ABL1 decreased in amount and activity in KPT-330-treated (1 µM, 72 hours) CD34 + CML-BC (n=3) and CD34 + /CD19 + B-ALL (n=3) progenitors ( Figure 4A ), likely due to the nuclear accumulation of SET and CIP2A, and subsequent restoration of PP2A activity as was observed in 48 hours) 32D-BCR/ABL cells, which presented levels of active PP2A similar to parental 32Dcl3 cells ( Figure 4B ).
To determine the relative contribution of PP2A in mediating the effects of KPT-330 on BCR-ABL1 activity/expression and survival of CML-BC progenitors, PP2A activity was constitutively suppressed in 32D-BCR/ABL cells upon expression of the SV40 small T antigen (small-t) 34 .
Annexin V/7AAD-staining revealed that 36h) induced apoptosis in ~60% and ~35% of parental and small-t-expressing 32D-BCR/ABL cells, respectively ( Figure 4C , left), indicating that ~50% of KPT-330-induced apoptosis is mediated by activation of PP2A.
Accordingly, small-t expression prevented the KPT-330-induced downregulation of BCR-ABL1 expression and activity (Figure 4C, right) . Consistent with the existence of a KPT-330-induced PP2A-dependent post-translational control of BCR-ABL1 activity/expression, BCR-ABL1 mRNA levels were not significantly changed in 36h )-treated cells compared to untreated and imatinib (1µM, 36h)-treated 32D-BCR/ABL cells ( Figure 4D ). Nonetheless, short exposure to 16h) did not reduced BCR-ABL1 activity while it impaired that of STAT5, Akt and p42/44 MAPKs ( Figure 4E ), suggesting that the pro-apoptotic activity of KPT-330 does not totally rely on inhibition of BCR-ABL1 kinase activity.
Similar to KPT-330, treatment with KPT-185 and/or KPT-207 also resulted in altered expression of the BCR-ABL1 downstream effectors hnRNP A1, hnRNP E2 and hnRNP K, inactivation and downregulation of BCR-ABL1 itself, activation of PP2A, and downregulation of the BCR-ABL1and hnRNP K-target c-Myc, likely as a result of both hnRNP K downregulation and PP2A activation (Supplemental Figure 1) . Thus, KPT-330 triggers apoptosis of BCR-ABL1-expressing cells by activating TSPs like PP2A and p53, and inhibiting the activity of oncogenes and proliferation/survival factors (e.g. BCR-ABL1, Akt, STAT5, MAPK, c-Myc, NF-kB) ( Figure 3D ).
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From
KPT-330 exerts strong anti-leukemic activity in a CML-BC mouse model.
To evaluate the therapeutic relevance of KPT-330 in Ph + acute leukemias in vivo, we employed an allograft model of CML-BC in which ICR-SCID mice were intravenously injected with 32D/BCR-ABL cells. After one week, nested RT-PCR-mediated detection of BCR-ABL1 transcripts in PB of cell-injected animals (n=20) confirmed engraftment of BCR-ABL1expressing cells ( Figure 5A ). RNA extracted from a 1:10 6 mixture of BCR-ABL1 + vs. parental 32Dcl3 cells, and from PB of age-matched mice was used as positive and negative controls, respectively ( Figure 5A ). Treatment with KPT-330 (15mg/kg; twice per week by oral gavage) was thereafter started in leukemic mice (n=12). As controls, a group of leukemic mice (n=8) received vehicle only whereas a group of healthy animals (n=7) received KPT-330 at the same regimen. When half of the vehicle-treated mice died (5 weeks post-cell injection), two moribund untreated, two KPT-330-treated, and one age-matched healthy animals were sacrificed and evaluated for signs of leukemia. While vehicle-treated animals displayed massive splenomegaly ( Figure 5B ) due to marked infiltration of immature myeloid cells (see also Figure 5D ), gross ( Figure 5B ) and histopathologic examination (not shown) of spleens from KPT-330-treated mice appeared similar to that of the age-matched animal ( Figure 5B ). Untreated leukemic mice all died with a median survival time of 5 weeks whereas 50% of KPT-330-treated animals died of leukemia mostly between week 8 and 11 post cell-injection ( Figure 5C ). At week 10 and 16 post-cell injection, nested RT-PCR on PB revealed that 3 of the living KPT-330-treated leukemic mice were negative for BCR-ABL1 ( Figure 5A ). Because after 15 weeks of drug treatment (16 weeks post cell-injection), 50% of the treated mice were still alive ( Figure 5C ) with no external signs of disease, all surviving KPT-330-treated animals (cell-injected and control drug-treated mice) and two age-matched healthy mice were sacrificed, and hematopoietic and nonhematopoietic organs were macro-and microscopically inspected for signs of leukemia. Gross examination revealed no differences between the two KPT-330-treated groups and agematched mice, including absence of splenomegaly in drug-treated cell-injected mice ( Figure 5B bottom panel). Furthermore, Wright-Giemsa-stained PB cytospins and H&E-stained sections of 1 3 BM, spleen and liver from KPT-330-treated (16 weeks) leukemic animals showed organ architecture and cellularity similar to those of drug-treated or age matched control animals with no infiltration of leukemic blasts, which were readily detectable in PB and organs of untreated leukemic animals ( Figure 5D ). Overall, KPT-330 treatment significantly increased survival (P=0.002) of leukemic mice by antagonizing disease evolution, and, as expected without inducing either toxicity or abnormal behavior in non-leukemic KPT-330-treated animals, which were all alive at the end of the study ( Figure 5C ).
Anti-leukemic activity of KPT-330 in a TKI-resistant CML-AP patient.
A 37 year-old male with CML-AP, hyperleukocytosis (WBC count >300x10 3 /µL), splenomegaly (13 cm below costal margin, BCM) and bone pain, whose disease was refractory to all available TKIs (including ponatinib) and to interferon, omacetaxine and azacitidine, received run-in dose of KPT-330 (12 mg/m 2 ) for one week and, thereafter, three oral therapeutic doses of KPT-330 (16.5 mg/m 2 ) on a compassionate use protocol after refusing BM transplant. After the first therapeutically effective dose (Table 1) , the patient experienced a significant reduction in bone pain, splenomegaly (from 13 cm to 4 cm BCM), WBC count (from 3x10 5 /µL to 7x10 3 /µL) and serum LDH (from 513 to 264 IU/L). Blood smears revealed a dramatic reduction, albeit not a complete disappearance, of immature myeloid blasts. Following one week from the third KPT-330 dose, WBC (37x10 3 /µL) and LDH (640 IU/L) increased. At this time the patient declined to undergo KPT-330 dose-escalation. Thus, the therapeutic efficacy of higher KPT-330 doses in this patient remains unknown, although the effect of KPT-330 dose-escalation is currently being evaluated in other patients.
DISCUSSION
Despite BCR-ABL1 playing a pivotal role in the emergence and maintenance of CML-BC and Ph + B-ALL 1,10 , the genetic heterogeneity of these malignancies may account for the lack of longterm response to TKI-based therapies 1, 4, 7, 9 . In fact, high levels of BCR-ABL1 expression/activity in Ph + acute leukemias aberrantly enhances genomic instability that, together with unfaithful DNA repair machinery, leads to an accumulation of molecular and chromosomal abnormalities, some of which result in the inactivation of tumor suppressors and/or activation of oncogenic factors acting in a BCR-ABL1-independent fashion 1,42,43 . Thus, a successful therapy of Ph + acute leukemias has to rely on the simultaneous targeting of BCR-ABL1 and other pathways playing an important role in the survival of leukemic stem/progenitor cells.
Indeed, we showed that BCR-ABL1 kinase-dependent and -independent signals, likely involving PI-3K and PKCs, contribute to enhance transcription of the nuclear export regulator XPO1 that, in turn, controls the survival of Ph + acute leukemia progenitors. Although this is not surprising given the involvement of XPO1 in several malignancies 22, [24] [25] [26] [27] [28] [29] [30] 32 and its pleiotropic activity on many cell functions 31,44 , the availability of specific inhibitors of XPO1 45 (e.g. KPT-330) with an acceptable safety profile make XPO1 an attractive target for the therapy of these unmanageable leukemias. In fact, KPT-330, a small molecule already in Phase I clinical trials for solid tumors and hematologic malignancies, not only efficiently and selectively impaired the leukemogenic potential of CML-BC and Ph + B-ALL BM progenitors and/or BCR-ABL1 + cell lines in both ex vivo and in an animal model, but also markedly reduced disease burden (e.g. WBC counts and splenomegaly) in a CML-AP patient. Notably, the KPT-330 concentrations used in all the ex vivo and in vivo studies were achieved in the current Phase I trials with a dose of 30 mg/m 2 , which is below the maximum tolerated dose 46 .
This, together with the evidence showing that the increased survival of long-term (15 weeks) KPT-330-treated leukemic animals, which was associated with the absence of BCR-ABL1 + circulating cells in 60% of treated mice, suggests that KPT-330 may safely be used in those Ph + acute leukemia patients who become refractory to TKIs-based therapies 4 . Moreover, we also For personal use only. on October 24, 2017. by guest www.bloodjournal.org From provide evidence that KPT-330 potentiates the effect of imatinib, suggesting that KPT-330 might be used in combination with TKIs especially in those cases in which TKI resistance is due to BCR-ABL1 amplification and blastic transformation 39, 47 ; in fact, the first XPO1 inhibitor discovered LMB, which shares the same XPO1-interacting surface with the SINEs but due to its lack of specificity is severely toxic when used in cancer patients 31, 48 , was elegantly shown to induce apoptosis of BCR-ABL1 + cells when used in combination with imatinib through a mechanism involving the LMB-induced nuclear-entrapment and inactivation/degradation of BCR-ABL1 39 . In KPT-330-treated BCR-ABL1 + cells, although we did not observe a BCR-ABL1 nuclear relocation (not shown), BCR-ABL1 expression/activity was markedly reduced, likely through post-translational and not transcriptional mechanisms, in primary CD34 + CML-BC and Ph + B-ALL BM cells, suggesting that other XPO1 targets might account for BCR-ABL1 downregulation. Similar effects on other oncogenic tyrosine kinases including Flt3 24 and BTK 25 have been reported in other hematologic malignancies.
Among the numerous XPO1 targets 44 there are the endogenous negative regulators of PP2A, SET 40 and CIP2A 44 , which were described as BCR-ABL1-regulated factors active in Ph + leukemias 33, 34, 41, 49 (Figure 3D ). Here we reported that KPT-330 treatment led to nuclear accumulation of SET and CIP2A proteins and, unexpectedly, of cytoplasmic relocation of the nucleocytoplasmic shuttling RNA binding protein hnRNP A1. Notably, hnRNP A1 is an important regulator of BCR-ABL1 leukemogenesis and controls SET mRNA nuclear export 11,15,33 ( Figure   3 ). Specifically, hnRNP A1 expression and nuclear export activity is enhanced in a dose-and kinase-dependent manner by BCR-ABL1 that, in turn, positively regulates the nuclear export of hnRNP A1 target mRNAs (e.g. SET, E2F3, and Bcl-X L .), and subsequently their protein levels 11, 15, 33, 35 . Because KPT-330 counteracts the RanGTP-mediated XPO1 transport of its cargo out of the nucleus and not vice versa 19, 31, 32 , it is unlikely that hnRNP A1 is directly exported by XPO1 even if in silico analysis 38 predicts hnRNP A1 to be an XPO1 target.
Nonetheless, we cannot exclude the possibility that KPT-330 may interfere with the hnRNP A1 M9-mediated nuclear export/import that is facilitated by transportin 1 (importin β2), a protein 1 6 similar to the XPO1 targets importin α1, α3 and α7 19, 44, 50 . Indeed, we provided evidence that shuttling-deficient M9 mutant hnRNP A1 proteins 35 are insensitive to KPT-330-mediated XPO1 inhibition.
Consistent with the effect of SET shRNA and with that of PADs (PP2A Activating drugs) that prevent SET-PP2A interaction 33,51 , the reduction of cytoplasmic SET and, likely, CIP2A 41 levels induced not only by KPT-330 but also by the other structurally-related SINEs (KPT-185 and resulted in reactivation of the PP2A tumor suppressor in BCR-ABL1 + myeloid precursors. Supporting the possibility that PP2A may play an important role as a mediator of KPT-330 anti-leukemic activity in Ph + acute malignancies stands also the evidence gained by using BCR-ABL1 + cells engineered to express the PP2A inhibitor small-t antigen. In fact, it appears that PP2A accounts for roughly 50% of the KPT-330-induced apoptosis. Importantly, rescue of PP2A activity in primary CML-BC and Ph + B-ALL progenitors as well as in animal models of TKI-sensitive and-resistant Ph + acute leukemias, is an event that, per se, is sufficient to catalyze a cascade of anti-mitotic and pro-apoptotic signals (including the SHP-1-mediated inactivation and proteasome-dependent degradation of BCR-ABL1) leading to killing of leukemic but not normal hematopoietic stem/progenitor cells 1,10,51 . Thus, it is not surprising that and other SINEs induced a marked PP2A-dependent (small-t sensitive) BCR-ABL1 inactivation/downregulation that, in turn, might also be responsible for the observed downregulation of hnRNP K and its target c-Myc, and of the differentiation-inhibitory factor hnRNP E2 15 .
Although important, KPT-330-induced PP2A reactivation is likely, not the only mechanism responsible for apoptosis of drug-treated Ph + acute leukemic progenitors; in fact, KPT-330 treatment of BCR-ABL1 + myeloid precursors induced nuclear accumulation of the p53 tumor suppressor and its transcriptional target p21, the ROS detoxifier and antagonist of cell cycle progression FoxO3a, and the negative NF-KB regulator IKBα, in agreement with the effect of SINEs on these XPO1 targets in other myeloid and lymphoid malignancies [22] [23] [24] [25] [26] 28, 32, 52 . Likewise, it seems that KPT-330 negatively also regulates the activity of BCR-ABL1 downstream effectors For personal use only. on October 24, 2017. by guest www.bloodjournal.org From like STAT5, Akt and MAPK independently from downregulation of BCR-ABL1 kinase activity.
Note that, binding and kinase assays exclude a direct effect of KPT-330 on these molecules and other factors regulating cell proliferation and survival (not shown).
Although further data on KPT-330's effectiveness in metastatic solid tumors and advanced hematological malignancies as well as its safety, tolerability and adverse effects will be soon be available through the two Phase I clinical trials, our preclinical and preliminary clinical data strongly support the immediate evaluation of this drug in CML-BC and Ph + B-ALL patients refractory to the available TKI-based therapies.
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Bottom Panel: Upon inhibition of XPO1 activity with the SINE KPT-330, the SET and CIP2A proteins are sequestered in the nucleus, which leads to activation of PP2A that, in turn, triggers inhibition/degradation of BCR-ABL1 contributing to cell death. Cytoplasmic accumulation of hnRNP A1 also contributes to decrease SET levels. In addition, nuclear accumulation of p53, p21, IκBα, and FoxO3a also likely contribute to impair leukemogenesis of Ph + acute leukemia progenitors.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Kaplan-Meier curve shows effect of KPT-330-treatment (15mg/kg, 2x weekly) on survival of SCID mice injected with 32D-BCR/ABL cells (n=10, red line). Untreated mice injected with cells (n=8, blue line) or KPT-330-treated mice that did not receive cells (n=7, green line) were used as controls. Survival was calculated by the Kaplan-Meier method, and the log-rank test evaluated the differences among survival distributions: P=0.002 (32D-BCR/ABL untreated vs.
